Cargando…

Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

BACKGROUND: Parkinson’s disease (PD) is one of the most important neurodegenerative disorders in elderly people. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are found in a large proportion of the patients with sporadic and familial PD. Mutations can occur at different locations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Meng-Ling, Wu, Ruey-Meei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375908/
https://www.ncbi.nlm.nih.gov/pubmed/35965315
http://dx.doi.org/10.1186/s12929-022-00844-9
_version_ 1784768047704178688
author Chen, Meng-Ling
Wu, Ruey-Meei
author_facet Chen, Meng-Ling
Wu, Ruey-Meei
author_sort Chen, Meng-Ling
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is one of the most important neurodegenerative disorders in elderly people. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are found in a large proportion of the patients with sporadic and familial PD. Mutations can occur at different locations in the LRRK2. Patients with LRRK2 ROC-COR mutations face an increased risk of typical motor symptoms of PD, along with cognitive decline. An animal model with a monogenic LRRK2 gene mutation is a suitable model for exploring the pathophysiology of PD and identifying potential drug therapies. However, the effect of homozygous (HOM) LRRK2 in PD pathophysiology is unclear. METHODS: We established human LRRK2 (hLRRK2) R1441G HOM transgenic (Tg) mice to explore the phenotype and pathological features that are associated with hLRRK2 R1441G Tg mouse models and discuss the potential clinical relevance. The open field test (OFT) was performed to examine motor and nonmotor behaviors. A CatWalk analysis system was used to study gait function. [(18)F]FDOPA PET was used to investigate functional changes in the nigrostriatal pathway in vivo. Transmission electron microscopy was used to examine the morphological changes in mitochondria and lysosomes in the substantia nigra. RESULTS: The R1441G HOM Tg mice demonstrated gait disturbance and exhibited less anxiety-related behavior and exploratory behavior than mice with hLRRK2 at 12 months old. Additionally, [(18)F]FDOPA PET showed a reduction in FDOPA uptake in the striatum of the HOM Tg mice. Notably, there was significant lysosome and autophagosome accumulation in the cytoplasm of dopaminergic neurons in R1441G hemizygous (HEM) and HOM mice. Moreover, it was observed using transmission electron microscopy (TEM) that the mitochondria of R1441G Tg mice were smaller than those of hLRRK2 mice. CONCLUSION: This animal provides a novel HOM hLRRK2 R1441G Tg mouse model that reproduces some phenotype of Parkinsonism in terms of both motor and behavioral dysfunction. There is an increased level of mitochondrial fission and no change in the fusion process in the group of HOM hLRRK2 R1441G Tg mouse. This mutant animal model of PD might be used to study the mechanisms of mitochondrial dysfunction and explore potential new drug targets. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00844-9.
format Online
Article
Text
id pubmed-9375908
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93759082022-08-15 Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism Chen, Meng-Ling Wu, Ruey-Meei J Biomed Sci Research BACKGROUND: Parkinson’s disease (PD) is one of the most important neurodegenerative disorders in elderly people. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are found in a large proportion of the patients with sporadic and familial PD. Mutations can occur at different locations in the LRRK2. Patients with LRRK2 ROC-COR mutations face an increased risk of typical motor symptoms of PD, along with cognitive decline. An animal model with a monogenic LRRK2 gene mutation is a suitable model for exploring the pathophysiology of PD and identifying potential drug therapies. However, the effect of homozygous (HOM) LRRK2 in PD pathophysiology is unclear. METHODS: We established human LRRK2 (hLRRK2) R1441G HOM transgenic (Tg) mice to explore the phenotype and pathological features that are associated with hLRRK2 R1441G Tg mouse models and discuss the potential clinical relevance. The open field test (OFT) was performed to examine motor and nonmotor behaviors. A CatWalk analysis system was used to study gait function. [(18)F]FDOPA PET was used to investigate functional changes in the nigrostriatal pathway in vivo. Transmission electron microscopy was used to examine the morphological changes in mitochondria and lysosomes in the substantia nigra. RESULTS: The R1441G HOM Tg mice demonstrated gait disturbance and exhibited less anxiety-related behavior and exploratory behavior than mice with hLRRK2 at 12 months old. Additionally, [(18)F]FDOPA PET showed a reduction in FDOPA uptake in the striatum of the HOM Tg mice. Notably, there was significant lysosome and autophagosome accumulation in the cytoplasm of dopaminergic neurons in R1441G hemizygous (HEM) and HOM mice. Moreover, it was observed using transmission electron microscopy (TEM) that the mitochondria of R1441G Tg mice were smaller than those of hLRRK2 mice. CONCLUSION: This animal provides a novel HOM hLRRK2 R1441G Tg mouse model that reproduces some phenotype of Parkinsonism in terms of both motor and behavioral dysfunction. There is an increased level of mitochondrial fission and no change in the fusion process in the group of HOM hLRRK2 R1441G Tg mouse. This mutant animal model of PD might be used to study the mechanisms of mitochondrial dysfunction and explore potential new drug targets. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00844-9. BioMed Central 2022-08-14 /pmc/articles/PMC9375908/ /pubmed/35965315 http://dx.doi.org/10.1186/s12929-022-00844-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Meng-Ling
Wu, Ruey-Meei
Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title_full Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title_fullStr Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title_full_unstemmed Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title_short Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
title_sort homozygous mutation of the lrrk2 roc domain as a novel genetic model of parkinsonism
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375908/
https://www.ncbi.nlm.nih.gov/pubmed/35965315
http://dx.doi.org/10.1186/s12929-022-00844-9
work_keys_str_mv AT chenmengling homozygousmutationofthelrrk2rocdomainasanovelgeneticmodelofparkinsonism
AT wurueymeei homozygousmutationofthelrrk2rocdomainasanovelgeneticmodelofparkinsonism